Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pulmonx Corp

3.11
-0.0100-0.32%
Post-market: 3.110.00000.00%16:54 EDT
Volume:228.44K
Turnover:700.42K
Market Cap:125.20M
PE:-2.15
High:3.13
Open:3.08
Low:2.97
Close:3.12
Loading ...

Pulmonx Corporation Concluded Annual Stockholders Meeting

Reuters
·
Yesterday

Pulmonx Is Maintained at Neutral by Citigroup

Dow Jones
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pulmonx (LUNG) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
05 May

Pulmonx Corporation’s Earnings Call Highlights Growth and Challenges

TIPRANKS
·
02 May

Pulmonx Price Target Cut to $9.00/Share From $10.00 by Piper Sandler

Dow Jones
·
01 May

Q1 2025 Pulmonx Corp Earnings Call

Thomson Reuters StreetEvents
·
01 May

Pulmonx Is Maintained at Buy by D. Boral Capital

Dow Jones
·
01 May

Pulmonx price target lowered to $9 from $10 at Piper Sandler

TIPRANKS
·
01 May

Piper Sandler Sticks to Their Buy Rating for Pulmonx (LUNG)

TIPRANKS
·
01 May

Pulmonx Corporation Reports Strong Q1 2025 Results

TIPRANKS
·
01 May

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
01 May

Pulmonx Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
01 May

Pulmonx reports Q1 EPS (36c), consensus (40c)

TIPRANKS
·
01 May

Pulmonx backs FY25 revenue view $96M-$98M, consensus $96.98M

TIPRANKS
·
01 May

Pulmonx Q1 EPS $(0.36) Beats $(0.41) Estimate, Sales $22.54M Beat $22.03M Estimate

Benzinga
·
01 May

BRIEF-Pulmonx Q1 EPS USD -0.36

Reuters
·
01 May

Pulmonx Reports First Quarter 2025 Financial Results

GlobeNewswire
·
01 May

Pulmonx Corp expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
29 Apr

Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

GlobeNewswire
·
17 Apr

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

PR Newswire
·
11 Apr